Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
86 hedge funds and large institutions have $108M invested in Poseida Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 19 closing their positions.
503% more call options, than puts
Call options by funds: $235K | Put options by funds: $39K
37% more capital invested
Capital invested by funds: $78.4M → $108M (+$29.2M)
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
9% less funds holding
Funds holding: 94 → 86 (-8)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.95M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.3M |
| 3 |
Renaissance Technologies
New York
|
+$509K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$468K |
| 5 |
Goldman Sachs
New York
|
+$456K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.19M |
| 2 |
Two Sigma Investments
New York
|
-$762K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$659K |
| 4 |
Morgan Stanley
New York
|
-$580K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$544K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFI
101
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$18.4K | -10,447 | Closed |
|
|
GCM
102
Gladius Capital Management
Chicago,
Illinois
| – | -$16.1K | -9,125 | Closed |
|
|
QC
103
Quent Capital
New York
| – | -$3.52K | -2,000 | Closed |
|
|
IPW
104
Impact Partnership Wealth
Marietta,
Georgia
| – | -$475 | -270 | Closed |
|
105
Simplex Trading
Chicago,
Illinois
| – | -$329 | -157 | Closed |
|
PSTX Hedge Fund Activity: Q3 2023 in Review
86 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2023, worth a combined $108M — up 37% from $78.4M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PSTX and 11 opened new positions — a net loss of 8 holders — while 23 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, adding an estimated $2.95M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.19M sold.
- 86 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2023, down from 94 in Q2 2023.
- Funds reported $108M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2023, up 37% quarter-over-quarter.
- 11 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2023 and 19 closed out, a net change of -8 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $2.95M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2023 was EcoR1 Capital, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2023.